Fresenius and Cellular Origins announce development agreement for Cell and Gene Therapy Manufacturing

Fresenius, via its operating company Fresenius Kabi, and Cellular Origins, a TTP Company, have entered an agreement to develop integration strategies for Fresenius Kabi’s portfolio of Cell Therapy Technologies within Cellular Origins’ Constellation™ automation platform. The agreement aims to leverage each company’s expertise in cell and gene therapies (CGTs) for digitally and physically integrating Fresenius Kabi’s suite of cell therapy processing technologies within Cellular Origins’ CGT robotic manufacturing platform Constellation™. Initial focus will be on integration of the Cue® Cell Processing System for automated small volume processing. Driving innovation by building momentum in cell and gene therapy, is a further milestone of #FutureFresenius.